Trevi Therapeutics to Showcase Breakthrough Chronic Cough Treatment at June Conferences

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical firm, is gearing up to participate in several key conferences this June. The company is focused on developing its investigational therapy, Haduvio™ (oral nalbuphine extended-release), aimed at treating chronic cough linked to idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Conferences and Presentations

The engagement starts with the American Cough Conference, set to take place from June 6-7, 2025, in Dulles, Virginia. Here, Trevi will present baseline demographics and characteristics from the RIVER trial, evaluating nalbuphine extended-release tablets for patients suffering from refractory chronic cough. Senior representatives, including Jennifer Good, the company’s President and CEO, will lead the presentations.

Following this, Trevi will attend the CPDD 87th Annual Scientific Meeting in New Orleans from June 14-18, 2025. On June 18, Dr. Thomas Sciascia, the Co-Founder and Chief Scientific Officer, will present a poster on the assessment of the abuse potential of nalbuphine in non-dependent recreational drug users.

The final engagement in June will be at the prestigious BIO International Convention in Boston, running from June 16-19. On June 17, Jennifer Good and Farrell Simon, Chief Commercial Officer, will provide a corporate presentation to spotlight Trevi's advances and the therapeutic potential of Haduvio.

Understanding Haduvio™

Haduvio is a groundbreaking investigational therapy, currently the only one shown to statistically significantly reduce cough frequency in clinical trials involving IPF and RCC patients. By acting on the cough reflex both centrally and peripherally, Haduvio utilizes its dual mechanism as a kappa agonist and mu antagonist (KAMA). This unique approach engages opioid receptors, which are essential for regulating chronic cough. Notably, nalbuphine is not classified as a controlled substance in the U.S., easing concerns about misuse relative to other opioid medications.

Chronic cough is a frequent yet debilitating condition affecting patients, particularly those with IPF, where up to 85% report experiencing it daily. With about 150,000 individuals diagnosed with IPF in the U.S., the condition leads to severe complications, including an increased likelihood of disease progression and diminished quality of life. Most importantly, there are currently no approved treatments for chronic cough associated with IPF, and off-label remedies yield little effectiveness.

Similarly, RCC represents a significant challenge, defined by a persistent cough lasting longer than eight weeks despite treatment for other underlying conditions. Affecting around 2-3 million Americans, RCC results in various negative outcomes, such as social embarrassment and impacts on mental health and quality of life.

Trevi aims to propose Haduvio as the trade name for their oral nalbuphine extended-release drug, intent on filling the treatment void for chronic cough conditions. Although the safety and effectiveness of Haduvio remain unverified by regulatory organizations, ongoing trials highlight its potential.

For updates and more information about Trevi Therapeutics, visit their official website at www.TreviTherapeutics.com and follow them on X (formerly Twitter) and LinkedIn.

Investor Contact: Jonathan Carlson, Trevi Therapeutics, Inc. (203) 654 3286 [contact email]

Media Contact: Rosalia Scampoli 914-815-1465 [contact email]